Further studies, including biological studies, are needed to understand the expression of surface molecules, how they vary over time and at the time of relapse, how much they influence the clinical presentation of the disease, and to better identify the role of potential drug targets in myeloma, including the orphan receptor GPRC5D, together with robust efficacy and safety data from clinical trials and real-world experience: this will better help us to identify a valid and rational strategy for sequencing. This evidence concerns the gene GPRC5D and plasma cell myeloma.